Topical cyclosporine A (CsA) 0.2% ointment applied twice daily is first-line treatment for immune-mediated keratoconjunctivitis sicca (KCS) in dogs, combined with a topical ocular lubricant applied as needed for palliative comfort.Veterinary Opht…+2
CsA works by blocking calcineurin-mediated interleukin-2 production, suppressing T-helper and cytotoxic T-cell infiltration of the lacrimal gland, resulting in regression of chronic corneal neovascularization and pigmentation and healing of indolent corneal ulcers.BMC Veterinary…+1 CsA is commercially available as Optimmune (0.2% ointment, Merck Animal Health).BMC Veterinary… Topical lubricants are used continuously and palliatively alongside immunosuppressive therapy rather than as a substitute for it.Veterinary Opht…
For dogs that do not respond adequately to CsA, topical tacrolimus applied twice daily is the established alternative, as both are calcineurin inhibitors with similar mechanisms of action.MSD Vet Manuals+1 Topical pimecrolimus twice daily has also demonstrated superior therapeutic effect compared to CsA in non-responders.BMC Veterinary… A 100 microgram subconjunctival injection of liposome-encapsulated sirolimus every 2 weeks showed similar efficacy and safety to daily CsA or tacrolimus over 14 weeks and represents an emerging alternative for dogs requiring less frequent dosing.Veterinary Opht…
CsA can cause ocular hypersensitivity in some patients and is less effective in advanced KCS.BMC Veterinary… Chronic topical immunosuppressive therapy carries risks of corneal and conjunctival infections and corneal squamous cell carcinoma.BMC Veterinary…
Monitor treatment response with the Schirmer Tear Test 1 (STT-1) and Tear Film Break-Up Time (TFBUT). STT-1 values and TFBUT are strongly correlated (r = 0.924), so improvement in one reflects improvement in the other.Veterinary Opht… Normal TFBUT is ≥20 seconds; a TFBUT <5 seconds indicates an unstable precorneal tear film.Veterinary Opht… For dogs treated with the aqueous calcineurin inhibitor SCY-641 twice daily, STT-1 values were significantly higher than placebo by day 14 and continued to improve through day 56, suggesting that 2 weeks is the earliest meaningful monitoring interval and 56 days captures the full initial response trajectory.Veterinary Opht…
In dogs with neurogenic KCS — identified by concurrent ipsilateral xeromycteria (dry nostril) — oral pilocarpine 2% is the treatment of choice, with 48% of treated dogs achieving resolution of clinical signs at a median of 4 months.Veterinary Opht… Neurogenic KCS should be suspected when concurrent facial neuropathy (38% of cases), peripheral vestibular syndrome (29%), or Horner's syndrome (15%) is present.Veterinary Opht… Underlying causes include idiopathic (53%), endocrinopathy (18%), otitis interna (12%), head trauma (9%), and iatrogenic causes such as post-total ear canal ablation (3%).Veterinary Opht… Long-lasting topical otic products have also been identified as a rare cause; most affected dogs regain normal tear function (STT ≥15 mm/min) spontaneously, with a median recovery of 37 days in non-referred dogs without deep corneal ulcers and 111 days in referred dogs.Journal of the…
For dogs with poor or incomplete response to immunosuppressive monotherapy, addition of an anti-inflammatory/antioxidant nutraceutical diet as an adjuvant produced significant improvement across all clinical parameters — tear production, conjunctival inflammation, corneal keratinization, corneal pigment density, and mucus discharge — over 60 days with no food-related adverse reactions.BMC Veterinary…+1
Surgical options — parotid duct transposition, buccal mucosal grafting, punctal occlusion, permanent partial tarsorrhaphy, and episcleral cyclosporine implantation — are reserved for patients who do not respond to medical management, with patient selection critical to outcome.Veterinary Opht…
| Treatment | Dose / Protocol | Efficacy | Key Caveat |
|---|---|---|---|
| CsA 0.2% ointment | Topical q12h | First-line; reduces corneal neovascularization and pigmentation | Less effective in advanced KCS; hypersensitivity possible BMC Veterinary…+1 |
| Tacrolimus | Topical q12h | Alternative for CsA non-responders | Similar mechanism to CsA MSD Vet Manuals+1 |
| Pimecrolimus | Topical q12h | Superior to CsA in non-responders | BMC Veterinary… |
| Liposomal sirolimus (SCJS) | 100 µg subconjunctival q2 weeks | Similar efficacy to daily CsA/tacrolimus at 14 weeks | Larger studies needed Veterinary Opht… |
| Oral pilocarpine 2% | Oral (dose per source) | 48% response rate; median resolution 4 months | Neurogenic KCS only Veterinary Opht… |
| Nutraceutical diet (adjuvant) | Combined with immunosuppressant × 60 days | Significant improvement in all clinical parameters | Adjuvant role in poor responders BMC Veterinary… |
Would you like guidance on how to distinguish neurogenic from immune-mediated KCS at initial presentation?